Summit Therapeutics Expands Ivonescimab Program into Bladder Cancer

What Happened

• On August 5, 2026, Summit Therapeutics Inc. (SMMT) announced via press release (attached as Exhibit 99.1 to its Form 8-K) the expansion of its global registration-enabling clinical program for ivonescimab into urothelial carcinoma (bladder cancer).
• The company plans to initiate the global, multi-regional Phase II/III HARMONi-GU1 trial to evaluate ivonescimab plus the antibody-drug conjugate enfortumab vedotin (EV) versus pembrolizumab plus EV as first-line treatment in patients with previously untreated locally advanced or metastatic urothelial carcinoma. Global site activations for HARMONi-GU1 are expected to begin later in 2026.

Key Details

• Filing date and disclosure: Form 8-K filed August 5, 2026; press release included as Exhibit 99.1.
• Trial name and phase: HARMONi-GU1, a global, multi-regional Phase II/III registration-enabling study.
• Treatment arms: ivonescimab + enfortumab vedotin (EV) vs pembrolizumab + EV.
• Patient population and timing: First-line therapy for previously untreated locally advanced or metastatic urothelial carcinoma; global site activations to start later this year (2026).

Why It Matters

• This expands Summit’s clinical development footprint beyond its prior indications and adds a registration‑enabling, late‑stage program in a new oncology indication.
• Initiating a Phase II/III global study and starting site activations in 2026 establishes near‑term clinical milestones to watch (enrollment progress, interim analyses, regulatory interactions), which can influence the company’s development timeline and investor outlook.
• Investors should monitor trial progress, enrollment updates, and any additional regulatory or partnership announcements tied to HARMONi‑GU1; the 8-K confirms the program expansion but does not provide financial projections or timelines beyond site activation timing.